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Abstract
Introduction—In this prospective study of localized prostate cancer patients and their partners,
we analyzed how partner issues evolve over time, focusing on satisfaction with care, influence of
cancer treatment and its impact on relationship with patient, cancer worry, and personal activities.
Aims—Our study aims were twofold: 1) to determine whether the impact of treatment on patients
and partners moderate over time and (2) if receiving surgery (i.e., radical prostatectomy)
influences partner issues more than other treatments.
Methods—Patients newly diagnosed with localized prostate cancer and their female partners
were recruited from 3 states to complete surveys by mail at 3 time points over 12 months.
Main Outcome Measures—The four primary outcomes assessed in the partner analysis
included satisfaction with treatment, cancer worry, and the influence of cancer and its treatment on
their relationship (both general relationship and sexual relationship).
Results—This analysis included 88 patient-partner pairs. At 6 months, partners reported that
cancer had a negative impact on their sexual relationship (39% - somewhat negative and 12% -
very negative). At 12 months, this proportion increased substantially (42% – somewhat negative
and 29% - very negative). Partners were significantly more likely to report that their sexual
relationship was worse when the patient reported having surgery (p=0.0045, OR=9.8025, 95% CI
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2.076–46.296). A minority of partners reported significant negative impacts in other areas
involving their personal activities (16% at 6 months and 25% at 12 months) or work life (6% at 6
months, which increased to 12% at 12 months).
Conclusion—From partners’ perspectives, prostate cancer therapy has negative impact on
sexual relationships, and appears to worsen over time.
Keywords
prostate cancer; partner; sexual function
Introduction
As with other major illnesses, men with newly diagnosed localized prostate cancer often
turn to their wives or significant others, (referred to here jointly as partners), for support.
The interactions between patients and partners may impact the patients’ treatment choices,
perceptions of outcomes following treatment, and their relationship with each other long
after cancer treatments have been completed. Despite these issues, relatively few studies
have evaluated the impact of a patient’s prostate cancer treatment choice on his partner’s
satisfaction with care, relationship with the patient, and quality of life. Very few studies
have specifically addressed the impact of declines in patient sexual function following
surgery on their partners. Studies of partners on this subject have been mixed: some suggest
that partners do not view sexual relationships as a priority; others find at least some
dissatisfaction with their current sexual relationship. No study has evaluated how partners’
relationships with prostate cancer patients evolves over time following treatment.
This longitudinal study evaluated partner issues and how they evolved over time,
particularly the issues associated with satisfaction with care, the influence of prostate cancer
and its treatment on the relationship with the patient, personal issues including satisfaction
with the sexual relationship, cancer worry, and activities and plans as a couple.
Aims
We explored two lines of inquiry: (1) does the influence of treatment on the items noted
above moderate over time; i.e., are the issues above less important as the time from initial
treatment lengthens; and (2) does receiving surgery (i.e., radical prostatectomy) influence
these partner issues more than other treatments or active surveillance?
Methods
Patient Population and Recruitment
The Family And Cancer Therapy Selection (FACTS) study conducted a prospective survey
of localized prostate cancer patients and their partners at three time points. Participant
recruitment was conducted at urology clinics in three states: the Medical University of South
Carolina Urology Department and Ralph H. Johnson Veterans Administration Medical
Center in Charleston, SC; three medical centers affiliated with the University of Southern
California in Los Angeles, CA; and the University of Texas Health Science Center at San
Antonio and the Audie Murphy Veterans Administration Medical Center in San Antonio,
TX.
Eligible patients had been recently diagnosed with localized prostate cancer (AJCC Stages I-
III, TNM Stages T1 – T3, N0, M0) and had not yet received primary treatment. Study
coordinators or research nurses reviewed lists of newly diagnosed localized prostate cancer
patients who had not been treated and were scheduled for clinic visits. If present at the
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treatment consultation with the patient, family members of patients were invited to
participate in the study by nurses or study coordinators. Patients without family members
present at their clinic visit were provided an approach packet to take home to their family
member. Family members originally included non-partner relationships (son or daughter,
sibling, etc.); later this analysis was restricted to partners only (both married and unmarried).
After nurses or study coordinators approached patients and partners at clinic visits and
conducted informed consent, participants took home a survey to return by mail. Study
coordinators conducted telephone follow-up to encourage the return of surveys. Participants
received $25 after completing the baseline survey. All study methods and materials were
approved by Institutional Review Boards at the study coordinating center (Fred Hutchinson
Cancer Research Center) and at each recruitment site.
Patient and Partner Surveys
We posed questions to partners and patients about various aspects of their cancer treatment
experience and the impact of cancer on their lives over time. Baseline surveys were
completed soon after diagnosis with follow-up surveys collected six months and 12 months
later. The mean time from diagnosis to participant baseline survey return was 79 days.
Although this mean response time was relatively short, we do not have any information
concerning sexual satisfaction prior to diagnosis. The survey development methods (focus
groups followed by cognitive interviews) and the taxonomy of items are described in detail
elsewhere.(1) A potential for response bias in the study cohort exists since couples who
completed the 6-month and 12-month follow-up surveys may be more motivated to
complete the surveys due to a negative treatment experience or unrealistic expectations
regarding the patient’s recovery.
Main Outcome Measures
The four primary outcomes assessed in the partner analysis included satisfaction with
treatment, cancer worry,(2–4) and the influence of cancer and its treatment on their
relationship (both general relationship and sexual relationship).
Patient-specific survey items included Expanded Prostate Index Composite (EPIC) sexual
domain summary scores, a general visual analogue scale measure of overall health and
satisfaction with treatment.(5) Partner survey items included personal issues (self-rated
overall health using a visual analogue scale, impact on career/work life, and hours spent on
chores previously handled by the patient), participation in social activities and reduced
ability to “go out/leave the home.” We also included the summary mental and physical
assessment questions from the SF-12 instrument.(6, 7)
Statistical Analysis
To assess the association between clinical and demographic variables on the four primary
outcomes, generalized linear mixed models were used. Generalized linear mixed models are
logistic regression models with a random within subject intercept to account for the
correlation on the repeated 6- and 12-month observations. Randomized quantile residuals
were used to graphically assess the fit of the models. Independent variables included survey
time (six versus 12 months), whether the patient received surgery, the patient’s sexual
baseline EPIC score, and the family member’s age at diagnosis, education, and physical and
mental SF-12 score at baseline.
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Of the 423 patients and 315 family members approached for the FACTS study, 240 patients
and 193 family members were eligible for inclusion in the study. After restricting the
analysis to patients and their female partners who completed all three surveys, 88 patients
and 88 partners were included in the evaluation reported here (Figure 1). Patients were on
average 4 years older than their female partners. Partner and patient demographics are
reported in Table 1 along with the patient comorbidities, classification of patient disease
risk, initial therapy, and baseline sexual satisfaction.
At the 12 month follow-up survey, the majority of patients reported having received surgery
(81%). Relatively small numbers of patients reported receiving radiation (17%), hormone
therapy (16%), or brachytherapy (9%). Only 7% reported receiving no therapy or active
surveillance. There was no statistically significant difference by site for patients who
received nonsurgical therapies, however the subgroup analysis was underpowered to detect
any differences between men who did and did not receive prostatectomy
Overall Assessment of Health and Satisfaction with Treatment: Comparison of Patients
and Partners
As gauged by a 0–100 visual analogue scale, patients’ average overall health decreased
slightly but not significantly at months six and 12 compared to baseline (baseline 84.1; six
months 82.1; 12 months 80.5; p =0.3037, p = 0.0735, respectively). The partner’s mean
reported overall health remained almost the same at baseline, six months, and 12 months
(79.7, 81.9, 81.4, respectively). (Data not shown)
The majority of partners and patients reported being satisfied with the patient’s treatment at
the six and 12-month follow-up periods (Table 2). From the generalized linear mixed model,
the only factor that was significantly associated with partner treatment satisfaction was
education, where partners with high school education or lower were less likely to be
satisfied with treatment (p=0.046, Odds Ratio=0.1926, 95% CI 0.038–0.967). This finding is
consistent with previously reported studies indicating that greater involvement in treatment
decision making leads to improved partner satisfaction with treatment outcomes. (8) There
were no significant associations from the regression model examining factors influencing
the partner’s general relationship with the patient.
Patient Sexual Function and the Partner’s Perception of their Sexual Relationship
As recorded by the EPIC questionnaire, patient’s reported urinary incontinence and sexual
function declined from baseline to six months, then improved somewhat at 12 months.
However, at 12 months sexual function and urinary incontinence scores were still
significantly lower than baseline (p< 0.0001). Bowel and urinary irritative symptoms did not
change appreciably over time (Table 3).
At six months, a slight majority of partners reported that cancer had a negative impact on
their sexual relationship (39% - somewhat negative and 12% - very negative). At 12 months,
the proportion of partners reporting that the cancer had a negative impact on their sexual
relationship increased substantially (42% – somewhat negative and 29% - very negative)
(Table 4). Partner reports of negative impact of therapy on their sexual relationship
correlated with patients reporting problems with their sexual function, and the degree of
correlation increased over time (Table 5). The generalized linear mixed model regression
assessing partner evaluations of the sexual relationship found that partners’ were
significantly more likely to report that their sexual relationship was worse when the patient
reported having surgery (p=0.0045, Odds Ratio=9.8025, 95% CI 2.076–46.296). There was
no significant associations between other factors—including the patient’s baseline EPIC
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sexual score, the partners age, education, and SF-12 physical and mental scores—and the
partner’s assessment of changes in their sexual relationship.
Partners’ Cancer Worry
At baseline 42% (n=37) of partners agreed with the statement that they were worried the
patient’s cancer would worsen; this number decreased to 26% (n=23) and 23% (n=20) at the
six and 12 month follow-up surveys respectively (data not shown). The generalized linear
mixed model found that partners who are white (versus all other races) were less likely to be
worried that their loved one’s cancer will get worse (p=0.0389, Odds Ratio=2.8848, 95% CI
1.057–7.873). Other factors were not significantly associated with cancer worry.
Impact on Partners’ Work and Activities
A majority of partners reported that the cancer experience had no impact on their work life/
career (84% at six months and 80% at 12 months); a small percentage reported a somewhat
or very negative impact on their work life/career (6% at six months, which increased to 12%
at 12 months) or a somewhat positive or very positive impact on their work life/career (10%
at six months, which decreased to 7% at 12 months). Over half of partners reported being
retired or not working (53% before diagnosis and 59% at 12 months). Most partners did not
change the number of hours they worked between the year before diagnosis and the 12
month survey (83%). Of those that did change the number of hours worked (n=15), the
average change was a decrease of 21 hours (S.D.= 21). At six months, 16% (n=14) reported
that the cancer diagnosis had a somewhat or very negative impact on their ability to do
things they wanted to do; this number increased to 25% (n=22) at 12 months (Data not
shown).
Impact on Social Activities and Activities Shared by the Couple
At six and 12 months, more than two thirds of partners reported that the patient’s cancer did
not impact their participation in social activities such as going out to dinner, visiting friends,
or going to the movies. The majority of partners reported that the cancer experience had no
impact on their ability to leave the house at either follow-up time point (68–69%); less than
one-fourth of partners reported a somewhat or very negative impact on their ability to leave
the house (20% at 6 months and 19% at 12 months). Similarly, at 12 months the majority of
partners (86%) reported they spent less than one hour per week or no time on chores the
patient used to do prior to diagnosis (Data not shown).
Discussion
We conducted a longitudinal, multi-site survey to better understand the impact of localized
prostate cancer and its treatment on partners of men with prostate cancer, focusing on how it
affected several personal issues and their relationships. Although their satisfaction with the
treatment was generally high, the proportion of partners reporting problems with their sexual
relationship increased substantially between six months and 12 months, such that at 12
months, more than seven out of 10 partners reported somewhat or very negative impacts on
their sexual relationship. In contrast, a minority of partners reported significant negative
impacts in other areas involving their relationship or their personal activities, including
work. While our study did not directly assess the impact of urinary function on men’s
quality of life, previous studies have reported that impaired urinary function did not limit
social, physical or occupational activities for the majority of men. (9, 10) Partner’s worry
about the patient’s cancer declined substantially over time. The partner reports about the
negative impact on their sexual relationship were largely mirrored by the patient reports,
including self-reports of difficulty as measured by the sexual function subscale of the EPIC
questionnaire. Partners were significantly more likely to report longer-term problems with
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their sexual relationship when the patient received surgery versus other therapies or active
surveillance.
We suspect that the decline in partner’s perception of their sexual relationship with the
patient is not a function of continued declines in patient sexual function. Average and
median patient sexual function scores from the EPIC questionnaire improved slightly
between 6 and 12 months, albeit rather modestly and well below baseline. Rather, we
propose that the continued poor function of patients was associated with partner
expectations that the couples sexual life would not improve as time from treatment
progressed. In agreement with this hypothesis, a psychological incongruence of adjustment
study by Ezer et al.(11) reported incongruent perceptions for couples through the first year
of prostate cancer treatment with regard to sexual symptoms and psychological distress.
Although our study did not collect information on patient or partner expectations directly,
our data indicate that a substantial fraction of partners who did not report problems at six
months changed their responses (in the negative) 12 months after diagnosis. Many partners
probably felt that a six month recovery period was to be expected, but at one year lost hope
that their sexual relationship was going to return to the pre-therapy state.
While the negative impact of prostate cancer therapy on men’s sexual function is well-
described, there has been less study of partner perspectives on this aspect of their
relationship. In a review of prior literature, Couper and colleagues reported that, “the focus
of concern of patients on their sexual function is not shared to an equal degree by their
partners.”(12) In a cross-sectional one-time survey, Neese and colleagues found that 38% of
partners reported at least some dissatisfaction with their current sexual relationship. Forty-
three percent had no interest in getting help for either their or their partner’s sexual issues.
(13) We did not ask about partner’s interest or intentions to seek help for sexual or other
issues related to the patient’s treatment.
Although several studies have shown that distress (or worry) among partners is relatively
high during the peri-diagnostic period, there is scant research to indicate how anxiety levels
change over time. However, a recent study by Lambert et al. reported that partners’ anxiety
rates within 4 months of the prostate cancer patient’s diagnosis were greater than both
population norms and the anxiety reported by the patients themselves. (14) Another dyadic
study highlighted the interdependence of psychological distress between couples, with
partners of patients reporting more emotional distress being more likely to report high
anxiety.. Conversely, alleviation of partner distress through emotional support and access to
educational resources led to improvements in patients self-reported physical and mental
health scores. (15) These findings suggest that health care practitioners may be able to
address distress concerns by targeting psychosocial interventions at the level of the couple
and identifying vulnerable couples who may benefit from counseling or educational tools to
manage treatment-related psychological distress. Our studies have not addressed the design
of interventions to assist patients and partners deal with psychological distress. Small to
medium effects of distress alleviation interventions are usually found for adult cancer
patients. (16)
Men have reported that the impact of prostate cancer therapy on sexual function is an
important drawback of therapy. In the Prostate Cancer Outcomes Study, men who received
surgery initially reported poorer sexual function compared to those who had other
treatments; however, this difference between treatment groups disappeared between two and
five years post diagnosis, largely due to worsening function in the nonsurgical group.(17) It
is possible that the difference we observed in partner’s reports of sexual problems between
surgically and non-surgically treated men would decline if the men in our survey also had
similar changes in sexual function over time.
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We note several limitations of our study. Our sample size was comparatively small and
limited to regional prostate cancer treatment centers. Moreover, our study population was
disproportionately white and men primarily received radical prostatectomy as treatment,
hence our results may not be generalizable to other populations, particularly
underrepresented minorities and men who opted for nonsurgical treatment options.. Not all
patients and partners completed all surveys, and thus our results are subject to response bias.
It is also unclear what effect participating in the study may have had on patients and partners
satisfaction with treatment given the low response rate for completing the surveys at all 3
time points. Our study lacked sufficient demographic data to characterize the differences
between survey responders and non-responders. It is plausible that couples who completed
the surveys are more motivated by their treatment experience, hence our sample may be
biased towards couples who experienced more difficulties with the patient’s treatment. A
drawback to dyadic study designs that has been described elsewhere (12) is the low response
rate of partners compared to patients, our study typifies this finding. Finally, we could not
validate patient or partner reports of specific treatments received through chart audits or
other means.
Few studies have surveyed partners of prostate cancer patients directly, even though it is
well established that patients and partners share in the mental and emotional disease
experience.(18, 19) Our study finds that partners report negative impacts on their sexual
relationship. This finding is supported by a growing body of literature suggesting that
prostate cancer has adverse effects on both the patient and the partner, particularly in
relation to sexual function, intimacy and communication. (20–24)
It is less clear to what extent this negative impact on sexual function is of concern to
partners, in light of the Couper et al. review and another study of 156 partners of patients
diagnosed with cancer (including prostate) that evaluated changes in the partner’s intimate
and sexual relationship with the patient. More than half of all women in this latter study
reported major decreases in their own sexual desire and intimacy.(25) Most of the studies
cited in the Couper review did not extend beyond six months, whereas our data suggests that
worry about cancer recurrence is higher than at 12 months. Perhaps as the partners’ concern
about the risk of cancer relapse eases, day-to-day issues related to the longer-term persistent
sequelae of therapy become more salient.
Based on our study findings, additional insight is needed to determine whether partners
perceive long-term negative effects on their sexual relationship to be a problem from their
own perspective, or whether the negative report reflects their perception of their partner’s
unhappiness and desire to improve it for their sake. This study should be replicated in a
larger cohort with a greater representation of patients who opt for non-surgical treatment
options to determine whether our study findings are relevant to patients who do not receive a
prostatectomy. Given the increasing number of prostate cancer survivors, future research is
needed to characterize the long-term impact of the disease burden on couples’ physical and
mental health, communication, relationship satisfaction and the impact on daily life for all
treatment types, including nonsurgical treatment options.. Such assessments are critical to
providing the educational resources and effective psychosocial interventions to support
couples surviving prostate cancer.
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Consort flow diagram for the Family And Cancer Therapy Selection (FACTS) study.
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Table 1
Participant demographics with patient comorbidities, classification of disease risk, initial therapy, and baseline
sexual satisfaction.
Patients Partners
N % N %
Total 88 100 88 100
Age
 <60 25 28% 37 42%
 60–64 18 20% 22 25%
 65–69 28 32% 20 23%
 70 + 17 19% 8 9%
Race
 White 74 84% 68 77%
 Black 4 5% 4 5%
 Hispanic/Asian 10 11% 13 15%
Employment
 Full-time /Part-time/Self-employed 60 68% n/a n/a
 Retired/Unemployed/Unknown 28 32% n/a n/a
Education
 High school or less 6 7% 11 13%
 Some college 20 23% 27 31%
 College graduate 29 33% 36 41%
 Graduate degree 30 34% 14 16%
 Unknown 3 3% 0 0%
Survey Site
 USC 56 64% n/a n/a
 UTHSCSA 16 18% n/a n/a
 MUSC 16 18% n/a n/a
Disease Classification
 Low risk 44 50% n/a n/a
 Moderate/High risk 44 50% n/a n/a
Comorbidities
 No other health problems 23 26% n/a n/a
 1 other health problem 39 44% n/a n/a
 2+ other health problems 26 30% n/a n/a
Initial therapy*
 Surgery 71 81% n/a n/a
 Brachytherapy 8 9% n/a n/a
 External Radiation 15 17% n/a n/a
 Hormone Therapy 14 16% n/a n/a
 Active Surveillance 6 7% n/a n/a
Baseline Sexual Satisfaction**
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Patients Partners
N % N %
 No or Small Problem 65 74% 68 77%
 Moderate or Big Problem 20 23% 15 17%
 Unknown 3 3% 5 6%
USC: University of Southern California; UTHSCSA: University of Texas Health Science Center at San Antonio; MUSC: Medical University of
South Carolina
*
Numbers add to more than 100% due to patients choosing multiple treatments
**
Patient baseline question asked about overall sexual function while partner baseline question asked how bothered they were by sexual difficulties
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Table 2
Patient and partner reported satisfaction with treatment.
Satisfaction Level
Patient satisfaction Partner satisfaction
At 6 months (N=86) At 12 months (N=88) At 6 months (N=84) At 12 months (N=88)
Not At All 1 (1%) 2 (2%) 1 (1%) 2 (2%)
Somewhat 11 (13%) 10 (11%) 10 (12%) 11 (13%)
Very 36 (42%) 30 (34%) 32 (38%) 22 (25%)
Completely 35 (41%) 41 (47%) 40 (48%) 44 (50%)
Not Sure 3 (3%) 5 (6%) 1 (1%) 9 (10%)
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Table 3
Patient reported Expanded Prostate Index Composite (EPIC) sexual and bowel and urinary function at
baseline, 6 months, and 12 months.
N Mean Median Range
Bowel (p=0.4206)
 Baseline 87 94.7 96.4 53.6–100
 6 Month 86 95.6 100.0 54.2–100
 12 Month 85 95.5 100.0 37.5–100
Sexual (p<0.0001)
 Baseline 87 55.7 65.4 0–94.2
 6 Month 87 30.7 18.0 0–95.8
 12 Month 85 37.5 36.2 0–100
Urinary Irritative (p=0.0909)
 Baseline 86 86.7 92.9 46.4–100
 6 Month 85 85.9 93.8 12.5–100
 12 Month 85 89.6 93.8 25–100
Urinary Incontinence (p<0.0001)
 Baseline 86 94.0 100 31.3–100
 6 Month 85 74.0 79.3 0–100
 12 Month 85 79.0 85.5 0–100
Higher EPIC score is better function. p-values reflect change between baseline and 12 month surveys.
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Table 5
Partner reported impact of cancer on sexual relationship, alongside patient reported overall problem with
sexual function (both at 6 months and 12 months).
Partner reported impact on
sexual relationship*
Patient overall sexual function 6 Months
(column %)
Patient overall sexual function 12 Months
(column %)
No or small problem Problem No or small problem Problem
Same or better 21 (58%) 14 (34%) 15 (38%) 7 (18%)
Worse 15 (42%) 27 (66%) 25 (63%) 33 (83%)
‘No or small problem’ includes responses that indicated no problem, very small problem, or small problem.
‘Problem’ includes responses that indicated moderate problem or big problem.
‘Same or better’ includes partner responses that indicated no impact, somewhat positive impact or very positive impact.
‘Worse’ includes partner responses that indicated very negative impact or somewhat negative impact.
*
At 6 months, the percent agreement between patient and partner is (21+27)/77 = 62% At 12 months, agreement is (15+33)/80 = 60%.
J Sex Med. Author manuscript; available in PMC 2014 December 01.
